Daniel J. Haraf to Adult
This is a "connection" page, showing publications Daniel J. Haraf has written about Adult.
Connection Strength
0.741
-
Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes. Int J Radiat Oncol Biol Phys. 2020 07 15; 107(4):662-671.
Score: 0.048
-
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. Oral Oncol. 2018 05; 80:16-22.
Score: 0.042
-
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer. Ann Oncol. 2016 05; 27(5):908-13.
Score: 0.036
-
Lymph node density--prognostic value in head and neck cancer. Head Neck. 2014 Feb; 36(2):266-72.
Score: 0.030
-
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma. Oral Oncol. 2013 Mar; 49(3):277-82.
Score: 0.029
-
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. Am J Clin Oncol. 2011 Aug; 34(4):356-61.
Score: 0.026
-
Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer. Head Neck. 2007 Jul; 29(7):632-7.
Score: 0.020
-
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
Score: 0.018
-
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):382-91.
Score: 0.018
-
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
Score: 0.017
-
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
Score: 0.015
-
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 2003 Apr; 14(4):564-9.
Score: 0.015
-
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
Score: 0.015
-
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
Score: 0.014
-
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J. 2001 Mar-Apr; 7(2):140-8.
Score: 0.013
-
Baseline Computed Tomography Radiomic and Genomic Assessment of Head and Neck Squamous Cell Carcinoma. J Comput Assist Tomogr. 2020 Jul/Aug; 44(4):546-552.
Score: 0.012
-
Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999 Jul-Aug; 5(4):219-23.
Score: 0.011
-
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol. 1999 Feb; 17(2):638-44.
Score: 0.011
-
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
Score: 0.011
-
Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy. Semin Oncol. 1998 Jun; 25(3 Suppl 8):28-32.
Score: 0.011
-
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996 Nov; 7(9):913-8.
Score: 0.009
-
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
Score: 0.009
-
Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res. 1996 Apr; 2(4):755-62.
Score: 0.009
-
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
Score: 0.008
-
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 01; 32(25):2735-43.
Score: 0.008
-
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
Score: 0.007
-
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope. 1992 Jun; 102(6):630-6.
Score: 0.007
-
Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030.
Score: 0.007
-
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
Score: 0.007
-
Chemoradiation for patients with large-volume laryngeal cancers. Head Neck. 2012 Aug; 34(8):1162-7.
Score: 0.007
-
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol. 1991 Oct; 14(5):419-26.
Score: 0.007
-
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol. 2011 Jul 26; 3:31.
Score: 0.007
-
Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):446-50.
Score: 0.007
-
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer. 2011 Oct 15; 117(20):4671-8.
Score: 0.007
-
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.
Score: 0.006
-
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9.
Score: 0.006
-
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. Head Neck. 2010 Nov; 32(11):1519-27.
Score: 0.006
-
Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. Radiother Oncol. 2010 Nov; 97(2):318-21.
Score: 0.006
-
Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol. 2010 Jun; 95(3):308-11.
Score: 0.006
-
Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20.
Score: 0.006
-
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
Score: 0.006
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.005
-
Free-flap reconstruction in the doubly irradiated patient population. Plast Reconstr Surg. 2008 Jul; 122(1):125-132.
Score: 0.005
-
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol. 2008 Oct; 19(10):1787-94.
Score: 0.005
-
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol. 2008 Sep; 19(9):1650-4.
Score: 0.005
-
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
Score: 0.005
-
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):59-67.
Score: 0.005
-
Aspiration in chemoradiated patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007 Dec; 133(12):1289-95.
Score: 0.005
-
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest. 2007 Sep; 25(6):435-44.
Score: 0.005
-
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):678-84.
Score: 0.005
-
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22.
Score: 0.005
-
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006 Jul 20; 24(21):3438-44.
Score: 0.005
-
Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck. 2006 Jan; 28(1):64-73.
Score: 0.004
-
Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope. 2006 Jan; 116(1):33-6.
Score: 0.004
-
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005 Mar-Apr; 11(2):140-6.
Score: 0.004
-
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83.
Score: 0.004
-
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004 Aug; 15(8):1179-86.
Score: 0.004
-
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32.
Score: 0.004
-
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55.
Score: 0.004
-
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004 Mar 15; 10(6):1956-62.
Score: 0.004
-
Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5.
Score: 0.004
-
Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol. 2003 Aug; 14(8):1306-11.
Score: 0.004
-
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
Score: 0.004
-
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 2002 Oct; 38(1):65-71.
Score: 0.004
-
An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck. Cancer. 2002 Jul 01; 95(1):98-104.
Score: 0.004
-
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
Score: 0.003
-
The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000 Aug; 126(8):950-6.
Score: 0.003
-
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann Oncol. 2000 Jun; 11(6):721-8.
Score: 0.003
-
Swallowing function in patients with head and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg. 2000 Mar; 126(3):371-7.
Score: 0.003
-
How Do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol. 2000 Feb; 18(4):877-84.
Score: 0.003
-
Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg. 2000 Jan; 69(1):245-9; discussion 249-50.
Score: 0.003
-
Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol. 1999 Mar; 17(3):1020-8.
Score: 0.003
-
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.
Score: 0.003
-
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol. 1998 Aug; 16(8):2715-21.
Score: 0.003
-
Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J Clin Oncol. 1998 Jun; 16(6):2157-63.
Score: 0.003
-
Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis. Ann Oncol. 1998 Jun; 9(6):647-51.
Score: 0.003
-
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
Score: 0.003
-
Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 1998 Jan; 16(1):159-64.
Score: 0.003
-
Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer. Qual Life Res. 1997 Apr; 6(3):274-84.
Score: 0.002
-
The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer. 1996 Jun 01; 77(11):2294-301.
Score: 0.002
-
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71.
Score: 0.002
-
Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. Semin Oncol. 1996 Apr; 23(2 Suppl 5):48-52.
Score: 0.002
-
The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol. 1995 Oct; 22(5 Suppl 12):8-12.
Score: 0.002
-
Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol. 1995 Apr; 13(4):876-83.
Score: 0.002
-
Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 1995 Mar; 2(2):101-6.
Score: 0.002
-
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol. 1995; 35(4):304-12.
Score: 0.002
-
Surgical management of the head and neck cancer patient following concomitant multimodality therapy. Laryngoscope. 1995 Jan; 105(1):97-101.
Score: 0.002
-
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol. 1994 Nov; 12(11):2351-9.
Score: 0.002
-
A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design. Semin Oncol. 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4.
Score: 0.002
-
Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994 Apr 30; 29(1):153-62.
Score: 0.002
-
Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy. Arch Otolaryngol Head Neck Surg. 1993 Jul; 119(7):743-6.
Score: 0.002
-
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
Score: 0.002
-
Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study. Cancer Chemother Pharmacol. 1993; 33(3):203-9.
Score: 0.002
-
Perspectives on combination chemotherapy with concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1992 Aug; 19(4 Suppl 11):47-56.
Score: 0.002
-
Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol. 1992 Jan; 3(1):79-81.
Score: 0.002
-
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol. 1992; 29(3):178-84.
Score: 0.002
-
Radiation therapy in the treatment of cervical cancer: the University of Chicago/Michael Reese Hospital experience. J Surg Oncol. 1990 Jul; 44(3):157-65.
Score: 0.002